10-Q: Tenax Therapeutics Q1 2026: Increased R&D, Cash Runway Extended

Tenax Therapeutics reports a significant increase in R&D expenses for Q1 2026, driven by ongoing Phase 3 trials for levosimendan, while extending its cash runway into early 2028.

Summary

• Tenax Therapeutics filed its Q1 2026 Form 10-Q, detailing financial performance and operational updates.
• The company reported a net loss of $15.7 million for the quarter ended March 31, 2026, compared to a net loss of $10.4 million in the same period of 2025.
• Research and development (R&D) expenses more than doubled to $11.5 million in Q1 2026 from $5.7 million in Q1 2025, primarily due to increased clinical trial costs for the LEVEL and LEVEL-2 studies.
• General and administrative (G&A) expenses decreased by 11% to $5.0 million from $5.7 million.
• Cash and cash equivalents increased to $118.8 million as of March 31, 2026, from $97.6 million at the end of 2025.
• The company believes its current cash position is sufficient to fund operations through at least the first quarter of 2028.
• Significant warrant and pre-funded warrant exercises in Q1 2026 provided $30.5 million in financing activities.
• A new Chief Financial Officer, Thomas R. Staab, II, was appointed effective May 11, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant increase in net loss and R&D expenses, despite the extended cash runway and successful financing activities.

Positives

• Cash and cash equivalents increased to $118.8 million as of March 31, 2026, providing a strong liquidity position.
• The company projects its current cash and cash equivalents, along with subsequent warrant exercises, will fund operations through at least Q1 2028, extending the cash runway.
• Financing activities provided $30.5 million in Q1 2026, primarily from warrant and pre-funded warrant exercises.
• Enrollment target of 230 patients for the Phase 3 LEVEL study was achieved in March 2026.
• The company has a clinician-driven drug development approach using established drugs with known safety profiles.
• Disclosure controls and procedures were deemed effective as of March 31, 2026.

Negatives

• Net loss increased by 51% to $15.7 million in Q1 2026 compared to $10.4 million in Q1 2025.
• Research and development expenses increased by 103% to $11.5 million in Q1 2026, impacting profitability.
• The company has an accumulated deficit of $383.2 million as of March 31, 2026.
• The company expects to continue incurring significant expenses and operating losses for at least the next several years.
• Stock-based compensation expense decreased by $0.3 million in R&D and $1.0 million in G&A, but this is due to prior grants vesting, not necessarily a positive operational change.

Risks

• The company has an accumulated deficit of $383.2 million and expects to continue incurring net losses for at least the next several years.
• The company will need substantial additional capital in the future to finalize development, commercialize levosimendan, potentially develop imatinib, and pursue other product candidates.
• Failure to obtain regulatory approval for levosimendan or imatinib could materially impact the business.
• The license agreement for levosimendan has a termination clause if no regulatory approval is granted in the United States by September 20, 2030.
• Stockholders may experience significant dilution if additional funds are raised by issuing common stock or convertible securities.
• Debt financings could result in significant interest expense and restrictive covenants.
• Collaboration and licensing arrangements may require relinquishing rights or granting unfavorable licenses.
• The company is subject to litigation in the normal course of business, though none are believed to be material.
• The risks disclosed in the Form 10-K for the year ended December 31, 2025, have not materially changed.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for at least the next several years as it advances its product candidates. Management believes its current cash and cash equivalents, along with subsequent warrant exercises, are sufficient to fund planned operations through at least the first quarter of 2028. The company plans to complete its Phase 3 LEVEL study and advance its LEVEL-2 study, with the intention to submit marketing authorization applications thereafter. Submission for imatinib is also planned following completion of a single Phase 3 trial.

Management Comments

• We believe this derisked approach of using already-approved drugs that provide well-established safety profiles from millions of patients, combined with a development path led by preeminent cardiovascular and pulmonary hypertension experts, puts us in a strong position to deliver breakthrough cardiopulmonary therapies designed to improve patients functioning and quality of life.
• Based on our current operating plan, we believe that our existing cash and cash equivalents as of March 31, 2026, along with cash received from warrant exercises subsequent to quarter end, will be sufficient to fund our planned operations through at least the first quarter of 2028.
• We are currently conducting the LEVEL trial and intend to recruit patients into the first half of 2026. We commenced our LEVEL-2 trial in December 2025 and are currently enrolling patients.
• Our ability to continue to pursue development of our products beyond March of 2028, including completion of a second Phase 3 oral levosimendan trial, will depend on obtaining license income, income from warrants exercised by investors should they elect to do so, or other financial resources.

Industry Context

StockSavvy.ai notes that Tenax Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on cardiopulmonary therapies. The company's strategy of repurposing approved drugs like levosimendan and imatinib for new indications like pulmonary hypertension is a common approach to mitigate some of the inherent risks and development timelines associated with novel drug discovery. However, the significant R&D expenditure and ongoing net losses are typical for companies at this stage of clinical development, highlighting the critical need for continued financing and successful trial outcomes.

Comparison to Industry Standards

• Biopharmaceutical companies in Phase 3 development typically incur substantial R&D expenses, with figures in the tens of millions of dollars per quarter not uncommon, as seen with Tenax's $11.5 million in Q1 2026.
• The cash runway of over 12 months, extending to Q1 2028 for Tenax, is a positive indicator, as many clinical-stage biotechs face liquidity challenges and often have shorter cash runways.
• The net loss reported by Tenax is consistent with industry peers in late-stage development, where revenue generation is minimal or non-existent, and significant investment in clinical trials is the primary driver of expenses.
• The successful exercise of warrants and pre-funded warrants, contributing $30.5 million in financing, is a common method for biotechs to raise capital, though it can lead to dilution for existing shareholders.

Management Changes

Legal Proceedings

• The company is subject to litigation in the normal course of business, none of which management believes will have a material adverse effect on the consolidated financial statements.

Stakeholder Impact

• Shareholders may experience significant dilution if the company raises additional capital by issuing shares or convertible securities.
• Creditors and debt holders may be impacted by the company's continued losses and need for future financing.
• Employees may be impacted by the company's financial performance and the need for continued investment in R&D, potentially affecting future growth and opportunities.
• Suppliers and CROs will continue to be paid for services rendered, but the company's ability to meet its obligations depends on its ongoing financing.

Next Steps

• Complete the ongoing Phase 3 LEVEL study of TNX-103 in PH-HFpEF.
• Advance the second global Phase 3 study, LEVEL-2.
• Submit marketing authorization applications following the completion of the two Phase 3 levosimendan trials.
• Submit an application for imatinib following completion of a single Phase 3 trial, when appropriate.
• Continue to fund operations through at least the first quarter of 2028 with existing cash and subsequent warrant exercises.
• The new CFO, Thomas R. Staab, II, will transition into his role, with consulting services from the interim CFO continuing until at least the end of May 2026.

Key Dates

Recommendation

While Tenax Therapeutics has a strong cash position and a clear development path for its lead candidates, the significant increase in net loss and R&D expenses, coupled with the ongoing need for substantial future capital, warrants a cautious approach. The extended cash runway provides a buffer, but the inherent risks in clinical-stage drug development and the potential for further dilution mean that investors should hold rather than aggressively buy until more definitive clinical trial data or regulatory milestones are achieved.

Keywords

Tenax Therapeutics, SEC Filing, 10-Q, Quarterly Report, Levosimendan, Pulmonary Hypertension, PH-HFpEF, Clinical Trials, R&D Expenses, Net Loss, Cash Runway, Financing